



NDA 207926/S-002

**SUPPLEMENT APPROVAL**

Akorn, Inc.  
Attention: John Franolic, PhD  
Vice President, Regulatory Affairs  
1925 West Field Court, Suite 300  
Lake Forest, IL 60045

Dear Dr. Franolic:

Please refer to your Supplemental New Drug Application (sNDA) dated and received February 19, 2019, and your amendment, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% and 10%. This Prior Approval supplemental new drug application provides for revised storage language in the labeling to correct a potential misunderstanding regarding the expiration date of opened topical ophthalmic bottles.

**APPROVAL & LABELING**

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter,

with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **CARTON AND CONTAINER LABELING**

Submit final printed carton and container labeling that are identical to the enclosed carton and container labeling, as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format – Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (April 2018, Revision 5)*. For administrative purposes, designate this submission “**Final Printed Carton and Container Labeling for approved NDA 207926/S-002.**” Approval of this submission by FDA is not required before the labeling is used.

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Eithu Z. Lwin, Regulatory Project Manager, at 301-796-0728.

Sincerely,

*{See appended electronic signature page}*

Wiley A. Chambers, MD  
Deputy Director  
Division of Transplant and Ophthalmology Products  
Office of Antimicrobial Products  
Center for Drug Evaluation and Research

### ENCLOSURE(S):

Content of Labeling  
Prescribing Information  
Carton and Container Labeling

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

WILEY A CHAMBERS  
03/01/2019 05:48:48 PM